Dimericon Therapeutics

Dimericon is a private biotech company focused on exploring crosslinked helix dimers (Dimericons) as therapeutics and templates for small molecule development. Dimericon’s technology targets hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers.The Seed round of financing will support preclinical studies to further develop the current lead compound to be an IND ready clinical candidate in hematological malignancies.